Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DuoSTAR KRAS gene editing program
- Development stage
- Preclinical
- Lead developer
- GeneLancet Biosciences
- Modality
- CRISPR-Cas9 → CRISPR Systems → Programmable Nucleases → Gene Editing → Gene Therapies, RNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
GeneLancet Biosciences is developing a broad-spectrum gene editing therapeutic program using their proprietary DuoSTAR (STAR editor) technology to target multiple KRAS oncogenic mutations, including G12D, G12C, G12V, G13A, and G13C variants. The STAR (Seek -> Tag -> Amend -> Release) editor is a precise multiple-turnover genome editing platform that uses ligated guide RNAs (LgRNA) and a modified Cas9 protein to edit and inactivate KRAS mutations in cancer cells. This gene editing modality is designed as a broad-spectrum therapeutic agent to treat a wide range of KRAS-driven cancers by inserting stop codons to ensure minimal truncated protein byproducts, potentially offering a one-time cure for various oncology indications.
- Other names
- KRAS broad-spectrum therapeutic programCancer Program
02
Targets
KRASG12C (Kirsten rat sarcoma viral oncogene homolog G12C)KRASG12D (Kirsten rat sarcoma viral oncogene homolog (KRAS) G12D mutant)KRASG12V (KRAS G12V)KRAS G13A (GTPase KRas G13A)KRAS G13C (Kirsten rat sarcoma viral oncogene homolog G13C mutant)
Beyond the preview
Go deeper on DuoSTAR KRAS gene editing program.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DuoSTAR KRAS gene editing program.